Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Colon Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Colorectal Cancer (1265
)
Rectal Cancer (79
)
Colorectal Adenocarcinoma (9
)
Colorectal Cancer (1265
)
Rectal Cancer (79
)
Colorectal Adenocarcinoma (9
)
›
Associations
(158)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
pembrolizumab
Sensitive: A2 - Guideline
Int J Surg Case Rep - 3 weeks (New C4)
pembrolizumab
Sensitive
:
A2
Int J Surg Case Rep - 3wk
pembrolizumab
Sensitive: A2 - Guideline
Int J Surg Case Rep - 3 weeks
pembrolizumab
Sensitive
:
A2
Int J Surg Case Rep - 3 weeks - (New C4)
No biomarker
Colon Cancer
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
mFOLFOX6
Sensitive: A2 - Guideline
mFOLFOX6
Sensitive
:
A2
mFOLFOX6
Sensitive: A2 - Guideline
mFOLFOX6
Sensitive
:
A2
NTRK3 fusion
Colon Cancer
NTRK3 fusion
Colon Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Colon Cancer
NTRK1 fusion
Colon Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Colon Cancer
NTRK2 fusion
Colon Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive
:
A2
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive
:
A2
RET fusion
Colon Cancer
RET fusion
Colon Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
FLOX
Resistant: A2 - Guideline
FLOX
Resistant
:
A2
FLOX
Resistant: A2 - Guideline
FLOX
Resistant
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
dostarlimab-gxly
Sensitive: A2 - Guideline
dostarlimab-gxly
Sensitive
:
A2
dostarlimab-gxly
Sensitive: A2 - Guideline
dostarlimab-gxly
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
KRAS wild-type
Colon Cancer
KRAS wild-type
Colon Cancer
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
NRAS wild-type
Colon Cancer
NRAS wild-type
Colon Cancer
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
FOLFIRI + ziv-aflibercept IV
Sensitive: A2 - Guideline
FOLFIRI + ziv-aflibercept IV
Sensitive
:
A2
FOLFIRI + ziv-aflibercept IV
Sensitive: A2 - Guideline
FOLFIRI + ziv-aflibercept IV
Sensitive
:
A2
BRAF wild-type
Colon Cancer
BRAF wild-type
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
NRAS wild-type
Colon Cancer
NRAS wild-type
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
KRAS wild-type
Colon Cancer
KRAS wild-type
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
FOLFIRINOX
Sensitive: A2 - Guideline
FOLFIRINOX
Sensitive
:
A2
FOLFIRINOX
Sensitive: A2 - Guideline
FOLFIRINOX
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
ramucirumab
Sensitive: A2 - Guideline
ramucirumab
Sensitive
:
A2
ramucirumab
Sensitive: A2 - Guideline
ramucirumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login